Recursion falls after quarterly revenue miss

Recursion Pharmaceuticals

06/05/2026 11:57

** Shares of drug developer Recursion Pharmaceuticals RXRX.O fall 3.9% to $3.25 premarket

** Co's Q1 revenue of $6.5 million misses analysts' average expectation of $15.8 million - LSEG data

** RXRX says total revenue primarily consists of revenue from collaboration agreements

** Says Roche ROPC.S collaboration revenue recognized was less in the current period due to the successful completion of certain project phases in the prior period

** Up to last close, stock was down 17.6% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))